Leukotriene Pathway Activation Associates with Poor Glycemic Control and with Cardiovascular Autonomic Neuropathy in Type 1 Diabetes

<div>Expressions of <i>ALOX5</i>, <i>MYD88</i>, and <i>LTB4R</i> mRNA in peripheral blood mononuclear cells (a–c) and plasma concentrations of leukotriene B4 (LTB4) (d) in type 1 diabetes (T1D) individuals and in nondiabetic controls (adjusted for sex, age, and use of angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, and statin).</div>

Mediators of Inflammation

fig1

Figure 1

Figure 1: Leukotriene Pathway Activation Associates with Poor Glycemic Control and with Cardiovascular Autonomic Neuropathy in Type 1 Diabetes 